Bio-rad Laboratories layoffs, on the record
Every job cut, severance charge and restructuring Bio-rad Laboratories reported in its annual reports, 2023 to 2025, quoted from the filings. Headcount went from approximately 8,030 to approximately 7,450.
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | approximately 8,030 | December 31, 2023 |
| 10-K for 2024 | approximately 7,700 | December 31, 2024 |
| 10-K for 2025 | approximately 7,450 | December 31, 2025 |
Job cuts, severance and restructuring
Our summaryCompany announced a strategy-driven restructuring plan in February 2021 that included eliminating certain positions, mainly in EMEA.
Word for word“In February 2021, we announced our strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance.” 10-K for 2023
Our summaryCompany approved a restructuring plan in February 2023 to streamline operations, recording employee termination benefits.
Word for word“Management approved three new restructuring plans in February 2023, June 2023, and October 2023 to implement identified opportunities to further streamline and improve operating performance.” 10-K for 2023
Our summaryCompany approved a restructuring plan in June 2023 that recorded employee termination benefits.
Word for word“From June 2023 to December 31, 2023, total restructuring-related expenses were $ 8.1 million, representing estimated termination benefits to employees.” 10-K for 2023
Our summaryCompany approved a restructuring plan in October 2023 that recorded employee termination benefits, expected to be substantially complete in early 2024.
Word for word“Our October 2023 restructuring plan is expected to be substantially complete in early 2024.” 10-K for 2023
Our summaryCompany reported total restructuring expense for 2023 within its income statement, with restructuring costs driving higher SG&A.
Word for word“The increase to SG&A expense was primarily driven by restructuring costs as well as higher facility-related expenses, partially offset by lower employee-related expenses.” 10-K for 2023
Our summaryInitiated a strategy-driven restructuring plan primarily affecting US operations, eliminating positions, consolidating functions, and relocating operations to lower cost locations.
Word for word“The restructuring plan is expected to eliminate a total of approximately 5 % of our workforce.” 10-K for 2024
Our summaryAnnounced expected timing and charge recognition for the February 2025 restructuring plan, with termination benefits such as cash severance and healthcare benefits.
Word for word“We anticipate that we will record approximately $ 30 million to $ 35 million of the charges related to this restructuring plan in the first quarter of fiscal year 2025 with the balance expected to be recorded by the end of fiscal year 2025.” 10-K for 2024
Our summaryReorganized aspects of European operations, a restructuring announced in February 2021 with additional restructurings approved in 2023, 2024, and 2025.
Word for word“We made significant changes to our organizational structure over the past few years, including the reorganization of aspects of our European operations that was announced in February 2021 and additional restructurings approved in 2023, 2024, and 2025.” 10-K for 2024
Our summaryReported higher restructuring costs in 2024 affecting gross margin and lower restructuring costs affecting SG&A compared with 2023.
Word for word“The increase in gross margin was primarily driven by favorable product mix and cost control measures, partially offset by higher restructuring and material costs.” 10-K for 2024
Our summaryManagement approved a new restructuring plan in February 2025 that eliminates certain positions, consolidates functions, and relocates some operations to lower cost locations, mainly in the U.S.
Word for word“In February 2025, management approved a new restructuring plan in furtherance of our ongoing program to improve operating performance.” 10-K for 2025
Our summaryThe company reported total expenses for the February 2025 restructuring plan, mostly estimated employee termination benefits.
Word for word“From February 2025 to December 31, 2025, total restructuring-related expenses for our February 2025 restructuring plan were $ 48.9 million, primarily representing estimated termination benefits to employees.” 10-K for 2025
Our summaryThe company said it has made significant organizational changes, including restructurings approved in 2023, 2024, and 2025.
Word for word“We made significant changes to our organizational structure over the past few years, including restructurings approved in 2023, 2024, and 2025.” 10-K for 2025
| Fiscal year ended | Restructuring charges | Cash paid for restructuring |
|---|---|---|
| 2016-12-31 | $12.5 million | $3 million |
| 2021-12-31 | $75.6 million | $14.2 million |
| 2022-12-31 | $0 | $16.8 million |
Bio-rad Laboratories filed 4 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Bio-rad Laboratories’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-13. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.